NO20034690D0 - Fremgangsmåte for behandling av tumorer ved administrering av tegafur, uracil, folinsyre og cyklofosfamid - Google Patents

Fremgangsmåte for behandling av tumorer ved administrering av tegafur, uracil, folinsyre og cyklofosfamid

Info

Publication number
NO20034690D0
NO20034690D0 NO20034690A NO20034690A NO20034690D0 NO 20034690 D0 NO20034690 D0 NO 20034690D0 NO 20034690 A NO20034690 A NO 20034690A NO 20034690 A NO20034690 A NO 20034690A NO 20034690 D0 NO20034690 D0 NO 20034690D0
Authority
NO
Norway
Prior art keywords
tegafur
cyclophosphamide
uracil
administration
folic acid
Prior art date
Application number
NO20034690A
Other languages
English (en)
Norwegian (no)
Other versions
NO20034690L (no
Inventor
Terry S Dugan
Eric Winer
Craig Bunnell
Jody Resller-Tatro
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20034690L publication Critical patent/NO20034690L/no
Publication of NO20034690D0 publication Critical patent/NO20034690D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20034690A 2001-04-26 2003-10-20 Fremgangsmåte for behandling av tumorer ved administrering av tegafur, uracil, folinsyre og cyklofosfamid NO20034690D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28672901P 2001-04-26 2001-04-26
PCT/US2002/012769 WO2002087335A1 (en) 2001-04-26 2002-04-22 Method for treating tumors by the administration of tegafur, uracil, folinic acid, and cyclophosphamide

Publications (2)

Publication Number Publication Date
NO20034690L NO20034690L (no) 2003-10-20
NO20034690D0 true NO20034690D0 (no) 2003-10-20

Family

ID=23099905

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20034690A NO20034690D0 (no) 2001-04-26 2003-10-20 Fremgangsmåte for behandling av tumorer ved administrering av tegafur, uracil, folinsyre og cyklofosfamid

Country Status (10)

Country Link
US (1) US6620816B2 (enExample)
EP (1) EP1399021A1 (enExample)
JP (1) JP2004533434A (enExample)
CA (1) CA2445262A1 (enExample)
CZ (1) CZ20032835A3 (enExample)
HU (1) HUP0303953A3 (enExample)
MX (1) MXPA03009681A (enExample)
NO (1) NO20034690D0 (enExample)
PL (1) PL373247A1 (enExample)
WO (1) WO2002087335A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4596220B2 (ja) 2001-06-26 2010-12-08 ソニー株式会社 画像処理装置および方法、記録媒体、並びにプログラム
EP1798689B1 (en) * 2001-06-26 2008-12-03 Sony Corporation Image processing apparatus and method, and image-capturing apparatus
US7951780B2 (en) * 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
JP2006160664A (ja) * 2004-12-07 2006-06-22 Vitamin C60 Bioresearch Kk フリーラジカル疾患予防治療用組成物
ES2373867T3 (es) * 2007-03-02 2012-02-09 The University Of Wollongong Composiciones y procedimientos para el suministro de agentes anticancerosos.
US20160067182A1 (en) * 2013-04-09 2016-03-10 Merrimack Pharmaceuticals, Inc. Methods and compositions for improving outcomes of liposomal chemotherapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4328229A (en) 1978-03-29 1982-05-04 Taiho Pharmaceutical Company Limited Anti-cancer composition for delivering 5-fluorouracil to cancer tissues
US5534513A (en) * 1991-09-05 1996-07-09 Taiho Pharmaceutical Company, Ltd. Antitumor potentiator and antitumor composition
US5688773A (en) * 1994-08-17 1997-11-18 The General Hospital Corporation Method of selectively destroying neoplastic cells

Also Published As

Publication number Publication date
US20020187956A1 (en) 2002-12-12
US6620816B2 (en) 2003-09-16
CZ20032835A3 (cs) 2007-06-20
HUP0303953A3 (en) 2005-05-30
JP2004533434A (ja) 2004-11-04
EP1399021A1 (en) 2004-03-24
NO20034690L (no) 2003-10-20
CA2445262A1 (en) 2002-11-07
MXPA03009681A (es) 2004-02-12
PL373247A1 (en) 2005-08-22
HUP0303953A2 (hu) 2004-04-28
WO2002087335A1 (en) 2002-11-07

Similar Documents

Publication Publication Date Title
NO20033910D0 (no) Fremgangsmåte og doseringsform for behandling av tumorer ved administreringav tegafur, uracil, folinsyre, paclitaxel og karboplatin
WO2003051366A3 (en) 3-(phenyl-alkoxy)-5-(phenyl)-pyridine derivatives and related compounds as kinase inhibitors for the treatment of cancer
NO20045677L (no) Inhibitorer av JAK- og CDK2-proteinkinaser
DE60219793D1 (de) Methode zur behandlung von zytokinvermittelten erkrankungen
NO20052760D0 (no) Fremgangsmate for behandling av kreft og beslektede fremgangsmater.
NO20070453L (no) Kondenserte heterocykliske kinase inhibitorer
WO2002062763A3 (en) Inhibition of raf kinase using quinolyl isoquinolyl or pyridyl ureas
PL406680A1 (pl) Inhibitory kinaz tyrozynowych
WO2004028454A3 (en) 1, 3, 5-triazines for treatment of viral diseases
IS2399B (is) Aðferðir til að framleiða 2-(N-metýl-N-metansúlfónýlamínó)pýrimidín, hýdroxýpýrimidín, halógenpýrimidín eða lífrænar súlfónýloxýpýrimidín afleiður ogefnasambönd sem fást með þeim
ATE355278T1 (de) Isochinolinon derivate als parp inhibitoren
WO2000063204A3 (en) Substituted azoles
NO20032229L (no) Fremgangsmåter for behandling av p38kinase-assosierte tilstander og pyrrolotriazin forbindelser nyttige som kinase inhibitorer
WO2002096361A3 (en) 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
ATE359079T1 (de) Verfahren zur behandlung von übelkeit, erbrechen, würgereiz oder jede kombination daraus
DK1383733T3 (da) Fremgangsmåde til fremstilling af 1,3-substituerede indener og aryl-sammenföjede azapolycykliske forbindelser
WO2002028861A3 (en) Methods and compounds for treating proliferative diseases
NO20034204L (no) Farmasöytiske kombinasjoner til behandling av kreft
MXPA03006817A (es) Metodo de tratamiento de enfermedades inflamatorias e inmunes usando inhibidores de la ikb cinasa (ikk).
WO2004043379A3 (en) Chemical compounds
NO20054361L (no) Benzensylfonamidderivater, fremgangsmate for fremstilling og anvendelse derav for behandlig av smerte
DE60108626D1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b] pyridinen als cyclin-abhängige kinase-hemmer
HK1053833A1 (zh) 取代苯基法呢基转移酶抑制剂
DE60211913D1 (de) Aryl- (oder heteroaryl-) azolylcarbynolderivatve zur behandlung von harninkontinenz
NO20034690L (no) Fremgangsmåte for behandling av tumorer ved administrering av tegafur, uracil, folinsyre og cyklofosfamid

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application